Combination of cisplatin-doxorubicin-cyclophosphamide in adenocarcinoma of unknown primary site: A phase II trial

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 24, Issue 4, 2001, Pages 372-375

  Guardiola, Emmanuel ^a   Pivot, Xavier ^a   Tchicknavorian, Xavier ^a   Magne, Nicola ^a   Otto, Josianne ^a   Thyss, Antoine ^a   Schneider, Maurice ^a  

^a CENTRE ANTOINE LACASSAGNE   (France)

Author keywords

Adenocarcinoma of unknown primary site; Chemotherapy; Cisplatin; Cyclophosphamide; Doxorubicin; Phase II

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN;

ADENOCARCINOMA; ADULT; AGED; ANEMIA; ARTICLE; BONE METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; EVALUATION; FEBRILE NEUTROPENIA; FEMALE; HUMAN; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MALE; NAUSEA AND VOMITING; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS, UNKNOWN PRIMARY; SURVIVAL ANALYSIS;

EID: 0034903515     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-200108000-00012     Document Type: Article

References (22)

1. Cisplatin-based combination chemotherapy in the treatment of poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown primary site: Results of a 12-year experience
2. Cost-effectiveness in the diagnosis and treatment of carcinoma of unknown primary origin
3. Unknown primary tumours
4. Metastatic and histologic presentations in unknown primary cancer
5. Empirical chemotherapy for adenocarcinoma of unknown primary tumor site
6. Fluorouracil, Adriamycin and mitomycin in the treatment of adenocarcinoma of unknown primary
7. Fluorouracil, Adriamycin and mitomycin-C for adenocarcinoma of unknown origin
8. Prognostic factors in metastatic carcinoma of unknown primary
9. Metastatic adenocarcinomas of unknown primary site: Prognostic variables and treatment results
10. Phase II trial of methotrexate-FAM in adenocarcinoma of unknown primary
11. Combination chemotherapy in metastatic tumors of unknown origin
12. Lack of value for cisplatin added to mitomycin-doxorubicin combination chemotherapy for carcinoma of unknown primary site
13. 5-Fluorouracil, doxorubicin and mitomycin C (FAM) combination chemotherapy for metastatic adenocarcinoma of unknown primary
14. Sequential chemotherapy for adenocarcinoma of unknown primary
15. Combination chemotherapy with 5-FU, Adriamycin, cyclophosphamide, and cis-platinum in the treatment of adenocarcinoma of unknown primary and undifferentiated carcinomas
16. Phase II trial of cisplatin for adenocarcinoma of unknown primary site
17. High dose intensity of cisplatin and etoposide in adenocarcinoma of unknown primary
18. Continuous infusion 5-fluorouracil, etoposide and cis-diamminedichloroplatinum in patients with carcinoma of unknown primary origin
19. Metastatic adenocarcinomas of unknown primary site: A randomized study of two combination-chemotherapy regimens
20. Management of patients with metastatic adenocarcinoma of unknown origin: A Southwest Oncology Group Study
21. Treatment and prognosis of metastatic carcinoma of unknown primary: Analysis of 100 patients
22. Treatment of the patient with adenocarcinoma of unknown origin